Leonardo de Andrade Mesquita

Leonardo de Andrade Mesquita

Auto-generated profile, based on publicly available information

Leonardo de Andrade Mesquita

Graduate Program in Medical Sciences: Endocrinology Universidade Federal do Rio Grande do Sul Porto Alegre Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
GPGiovana F Piccoli
Giovana F Piccoli
LMLeonardo A Mesquita
Leonardo A Mesquita
CSCinara Stein
Cinara Stein
MAMarina Aziz
Marina Aziz
MZMaira Zoldan
Maira Zoldan
Fernando GerchmanFernando Gerchman
Fernando Gerchman
Context: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the Liraglutide Clinical Development Program, subjects treated with a glucagon-like peptide-1 receptor agonist (GLP-1RA) had a higher absolute number of breast cancer events. Objective: To assess whether patients treated with GLP-1RAs had a higher risk of breast neoplasms. Data Sources: We searched MEDLINE, Embase, Web of Science, and CENTRAL from July 31, 2019 to February 8, 2020. Study Selection: Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks. Data Extraction: Researchers extracted study-level data and assessed within-study risk of bias with the RoB 2.0 tool and quality of evidence with Grading of Recommendations Assessment, Development and Evaluation (GRADE). Data Synthesis: We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms. Overall methodological quality was high. Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76–1.26). Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences. The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48–2.01). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results. Conclusions: Treatment with GLP-1RAs for obesity and diabetes does not increase the risk of breast neoplasms.

21 June 2023 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
LMLeonardo de Andrade Mesquita
Leonardo de Andrade Mesquita
LWLaura Fink Wayerbacher
Laura Fink Wayerbacher
GSGilberto Schwartsmann
Gilberto Schwartsmann
Fernando GerchmanFernando Gerchman
Fernando Gerchman
The proportion of deaths attributable to cancer is rising, and malignant neoplasms have become the leading cause of death in high-income countries. Obesity and diabetes are now recognized as risk factors for several types of malignancies, especially endometrial, colorectal, and postmenopausal breast cancers. Mechanisms implicated include disturbances in lipid-derived hormone secretion, sex steroids biosynthesis, hyperinsulinemia, and chronic inflammation. Intentional weight loss is associated with a mitigation of risk for obesity-related cancers, a phenomenon observed specially with bariatric surgery. The [...] ABSTRACT The proportion of deaths attributable to cancer is rising, and malignant neoplasms have become the leading cause of death in high-income countries. Obesity and diabetes are now recognized as risk factors for several types of malignancies, especially endometrial, colorectal, and postmenopausal breast cancers. Mechanisms implicated include disturbances in lipid-derived hormone secretion, sex steroids biosynthesis, hyperinsulinemia, and chronic inflammation. Intentional weight loss is associated with a mitigation of risk for obesity-related cancers, a phenomenon observed specially with bariatric surgery. The

1 December 2020 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
LMLeonardo de Andrade Mesquita
Leonardo de Andrade Mesquita
GPGiovana Fagundes Piccoli
Giovana Fagundes Piccoli
GNGabriella Richter Natividade
Gabriella Richter Natividade
BSBernardo Frison Spiazzi
Bernardo Frison Spiazzi
VCVerônica Colpani
Verônica Colpani
Fernando GerchmanFernando Gerchman
Fernando Gerchman

16 August 2018 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
LMLeonardo de Andrade Mesquita
Leonardo de Andrade Mesquita
LALuciana Pavan Antoniolli
Luciana Pavan Antoniolli
GCGiordano Fabricio Cittolin-Santos
Giordano Fabricio Cittolin-Santos
Fernando GerchmanFernando Gerchman
Fernando Gerchman
The shapes of the plasma glucose concentration curve during the oral glucose tolerance test are related to different metabolic risk profiles and future risk of type 2 DM. We sought to further analyze the relationship between the specific shapes and hyperglycemic states, the metabolic syndrome and hormones involved in carbohydrate and lipid metabolism, and to isolate the effect of the shape by adjusting for the area under the glucose curve. One hundred twenty one adult participants underwent a 2-h oral glucose tolerance test and were assigned to either the monophasic (n = 97) or the biphasic (n = 24) group based upon the rise and fall of their plasma glucose concentration. We evaluated anthropometric measures, blood pressure, lipid profile, high-sensitivity C-reactive protein, glycated hemoglobin, insulin sensitivity, beta-cell function, C-peptide, glucagon, adiponectin and pancreatic polypeptide. Subjects with monophasic curves had higher fasting and 2-h plasma glucose levels, while presenting lower insulin sensitivity, beta-cell function, HDL cholesterol, adiponectin and pancreatic polypeptide levels. Prediabetes and metabolic syndrome had a higher prevalence in this group. Glycated hemoglobin, total cholesterol, triglycerides, high-sensitivity C-reactive protein and glucagon were not significantly different between groups. After adjusting for the area under the glucose curve, only the differences in the 1-h and 2-h plasma glucose concentrations and HDL cholesterol levels between the monophasic and biphasic groups remained statistically significant. Rates and intensity of metabolic dysfunction are higher in subjects with monophasic curves, who have lower insulin sensitivity and beta-cell function and a higher prevalence of prediabetes and metabolic syndrome. These differences, however, seem to be dependent on the area under the glucose curve.

23 February 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
LMLeonardo A. Mesquita
Leonardo A. Mesquita
BSBernardo F. Spiazzi
Bernardo F. Spiazzi
GPGiovana F. Piccoli
Giovana F. Piccoli
DNDaniela A. Nogara
Daniela A. Nogara
GNGabriella Richter Natividade
Gabriella Richter Natividade
Fernando GerchmanFernando Gerchman
Fernando Gerchman